Welcome to Multibagg AI
Log in to access personalized features
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stock
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Discovery themes featuring this stock
Vimta Labs Ltd (VIMTALABS) is currently trading at 612.70 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Vimta Labs Limited is a comprehensive contract research and testing organization serving industries like pharmaceuticals, food, electronics, and environment testing. With expertise in drug discovery and development, it offers pivotal support for numerous sectors. The company has experienced a commendable 10.2% year-on-year revenue growth as of Q3 FY26, showcasing resilience and effective market penetration. The diverse testing services offered have significantly contributed to these earnings. Strategic capacity expansion, especially in biologics and electronics sectors, hints at Vimta Labs Limited's commitment to seize emerging opportunities, reflecting a calculated approach to maximize its operational footprint. International business continues to bolster Vimta Labs Limited's financial trajectory, with exports contributing around 39% of their income, underscoring its strong global presence, particularly in pharmaceutical analytical services.
Over the past 52 weeks, Vimta Labs Ltd has traded between a low of ₹377.30 and a high of ₹828.85. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Vimta Labs Ltd has a market capitalization of approximately 2,754.85. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Vimta Labs Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 45.31 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 2,754.85 Cr, Vimta Labs Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Vimta Labs Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Vimta Labs Ltd is 45.31. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Q4 FY26 total income was Rs 112 crore and profit after tax was Rs 21.11 crore, compared with Rs 96.08 crore income and Rs 18.32 crore PAT in Q4 FY25.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
616.00 | 2,755 Cr | 45.31 | 6.03 | 0.32 | 16.97 | 21.60 | 14.17 | ||
109.08 | 256 Cr | -19.23 | 1.30 | 0.00 | 2.81 | 6.68 | -0.76 | ||
16.69 | 244 Cr | 41.32 | 7.86 | 0.00 | 13.73 | 15.37 | 35.38 | ||
77.50 | 221 Cr | -86.53 | 3.36 | 0.00 | 5.50 | 6.70 | 3.92 | ||
80.50 | 161 Cr | 31.53 | 2.24 | 0.00 | 1.60 | 4.43 | 4.80 | ||
31.80 | 109 Cr | 32.24 | 1.92 | 0.00 | 5.01 | 4.64 | 5.08 | ||
16.35 | 24 Cr | 18.73 | 0.62 | 0.00 | 3.30 | 5.52 | 2.51 | ||
| Median: 7 Co. | — | 77.50 | 221 Cr | 31.53 | 2.24 | 0.00 | 5.01 | 6.68 | 4.80 |
Bearish
3
Neutral
6
Bullish
5
Bearish
17
Neutral
6
Bullish
23
Bearish
14
Neutral
0
Bullish
18
Vimta Labs Limited is a comprehensive contract research and testing organization serving industries like pharmaceuticals, food, electronics, and environment testing. With expertise in drug discovery and development, it offers pivotal support for numerous sectors.
The company has experienced a commendable 10.2% year-on-year revenue growth as of Q3 FY26, showcasing resilience and effective market penetration. The diverse testing services offered have significantly contributed to these earnings.
Strategic capacity expansion, especially in biologics and electronics sectors, hints at Vimta Labs Limited's commitment to seize emerging opportunities, reflecting a calculated approach to maximize its operational footprint.
International business continues to bolster Vimta Labs Limited's financial trajectory, with exports contributing around 39% of their income, underscoring its strong global presence, particularly in pharmaceutical analytical services.
Healthcare Services
Healthcare Research, Analytics & Technology
2,739 Cr
High Risk
45.0
65.7
1.0
6.0
828.85
377.30
Sales CAGR
Profit CAGR
ROE
ROCE
